Colitis Case Study

  • Murata I, Satoh K, Yoshikawa I, Masumoto A, Sasaki E, Otsuki M. Recurrent subcutaneous abscess of the sternal region in ulcerative colitis. Am J Gastroenterol. 1999 Mar. 94(3):844-5. [Medline].

  • Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000 Aug. 75(8):802-6. [Medline].

  • Egan CA, Meadows KP, Zone JJ. Ulcerative colitis and immunobullous disease cured by colectomy. Arch Dermatol. 1999 Feb. 135(2):214-5. [Medline].

  • Esteve M, Gisbert JP. Severe ulcerative colitis: at what point should we define resistance to steroids?. World J Gastroenterol. 2008 Sep 28. 14(36):5504-7. [Medline]. [Full Text].

  • Shen B. Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis. 2009 Feb. 15(2):284-94. [Medline].

  • Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008 Sep 28. 14(36):5508-11. [Medline]. [Full Text].

  • Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001 Mar. 120(4):841-7. [Medline].

  • Kaufman SS, Vanderhoof JA, Young R, Perry D, Raynor SC, Mack DR. Gastroenteric inflammation in children with ulcerative colitis. Am J Gastroenterol. 1997 Jul. 92(7):1209-12. [Medline].

  • Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008 Oct. 125(2):145-53. [Medline].

  • Kuenzig ME, Lee SM, Eksteen B, et al. Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration. BMC Gastroenterol. 2016 Dec 21. 16(1):143. [Medline].

  • Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007 Jul 26. 448(7152):427-34. [Medline].

  • Lindberg E, Magnusson KE, Tysk C, Jarnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut. 1992 Jul. 33(7):909-13. [Medline]. [Full Text].

  • Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009 Dec. 41(12):1330-4. [Medline]. [Full Text].

  • Vasiliauskas E. Serum immune markers in inflammatory bowel disease. Gastroenterology and Endoscopy News. Available at http://www.gastroendonews.com.

  • Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):730-4. [Medline].

  • Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001 Mar. 96(3):758-65. [Medline].

  • Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999 Apr. 134(4):447-52. [Medline].

  • Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Apr. 26(4):386-92. [Medline].

  • Duggan AE, Usmani I, Neal KR, Logan RF. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut. 1998 Oct. 43(4):494-8. [Medline]. [Full Text].

  • Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001 Mar 15. 344(11):808-14. [Medline].

  • Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2000 May. 95(5):1213-20. [Medline].

  • Almeida MG, Kiss DR, Zilberstein B, Quintanilha AG, Teixeira MG, Habr-Gama A. Intestinal mucosa-associated microflora in ulcerative colitis patients before and after restorative proctocolectomy with an ileoanal pouch. Dis Colon Rectum. 2008 Jul. 51(7):1113-9. [Medline].

  • Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000 Aug. 95(8):1949-54. [Medline].

  • Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr. 1998 Feb. 26(2):129-35. [Medline].

  • Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology. 1981 Dec. 81(6):1115-24. [Medline].

  • Cotran RS, Collins T, Robbins SL, Kumar V. Pathologic Basis of Disease. Philadelphia, Pa: WB Saunders; 1998.

  • Jang ES, Lee DH, Kim J, Yang HJ, Lee SH, Park YS. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009 Sep-Oct. 56(94-95):1304-9. [Medline].

  • Gooding IR, Springall R, Talbot IC, Silk DB. Idiopathic small-intestinal inflammation after colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2008 Jun. 6(6):707-9. [Medline].

  • Slatter C, Girgis S, Huynh H, El-Matary W. Pre-pouch ileitis after colectomy in paediatric ulcerative colitis. Acta Paediatr. 2008 Mar. 97(3):381-3. [Medline].

  • Falcone RA Jr, Lewis LG, Warner BW. Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg. 2000 Mar-Apr. 4(2):201-6. [Medline].

  • Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30. 330(26):1841-5. [Medline].

  • Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 2000 Aug. 95(8):2000-8. [Medline].

  • Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr. 96(4):1116-22. [Medline].

  • de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000 Dec. 27(12):2860-5. [Medline].

  • Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998 Nov. 27(5):580-3. [Medline].

  • Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997 Aug. 92(8):1285-8. [Medline].

  • Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999 Nov. 94(11):3258-62. [Medline].

  • Calabrese C, Fabbri A, Gionchetti P, et al. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther. 2007 Jun 1. 25(11):1311-6. [Medline].

  • Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc. 2016 Dec 16. 8(20):723-32. [Medline].

  • Carucci LR, Levine MS. Radiographic imaging of inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar. 31(1):93-117, ix. [Medline].

  • Eisenberg RL. Gastrointestinal Radiology: A Pattern Approach. Philadelphia, Pa: Lippincott-Raven; 1998. 602-8.

  • Wiesner W, Steinbrich W. [Imaging diagnosis of inflammatory bowel disease]. Ther Umsch. 2003 Mar. 60(3):137-44. [Medline].

  • van den Broek FJ, Fockens P, Dekker E. Review article: New developments in colonic imaging. Aliment Pharmacol Ther. 2007 Dec. 26 Suppl 2:91-9. [Medline].

  • Deutsch DE, Olson AD. Colonoscopy or sigmoidoscopy as the initial evaluation of pediatric patients with colitis: a survey of physician behavior and a cost analysis. J Pediatr Gastroenterol Nutr. 1997 Jul. 25(1):26-31. [Medline].

  • Matsumoto T, Nakamura S, Jin-No Y, et al. Role of granuloma in the immunopathogenesis of Crohn's disease. Digestion. 2001. 63 Suppl 1:43-7. [Medline].

  • Basson MD, Etter L, Panzini LA. Rates of colonoscopic perforation in current practice. Gastroenterology. 1998 May. 114(5):1115. [Medline].

  • Polter DE. Risk of colon perforation during colonoscopy at Baylor University Medical Center. Proc (Bayl Univ Med Cent). 2015 Jan. 28(1):3-6. [Medline].

  • Makkar R, Bo S. Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013 Sep. 9(9):573-83. [Medline].

  • [Guideline] Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006 Apr. 63(4):558-65. [Medline].

  • Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: a comprehensive review. Drugs. 2017 Feb. 77(2):159-73. [Medline].

  • Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):601-16. [Medline].

  • Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar. 33(6):672-8. [Medline].

  • Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec. 21(12):827-34. [Medline].

  • Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec. 137(6):1934-43.e1-3. [Medline].

  • Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec. 106(12):2070-7; quiz 2078. [Medline].

  • D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul. 107(7):1064-77. [Medline].

  • Barber J Jr. FDA approves Uceris for ulcerative colitis. Medscape Medical News. Jan 18, 2013. Available at http://www.medscape.com/viewarticle/777917. Accessed: January 28, 2013.

  • Sandborn WJ, Danese S, D'Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar. 41(5):409-18. [Medline].

  • Uceris Rectal Foam (budesonide [package insert]. Raleigh, NC 27615: Distributed by Salix Pharmaceuticals, Inc. (under license from Dr. Falk Pharma). October 8, 2014. Available at [Full Text].

  • Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):590-9. [Medline].

  • Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):644-59, quiz 660. [Medline].

  • Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct. 137(4):1250-60; quiz 1520. [Medline].

  • Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 Mar. 45(5):617-30. [Medline].

  • Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun. 60(6):780-7. [Medline].

  • Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb. 142(2):257-65.e1-3. [Medline].

  • Sandborn WJ, Feagan BG, Marano CW, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis (UC): Pursuit SC (Abstract #943d) Presented at Digestive Disease Week, May 21, 2012. San Diego, CA.

  • Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2011 Apr. 106(4):771-7. [Medline].

  • Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22. 369(8):699-710. [Medline].

  • Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):661-73. [Medline].

  • Sakuraba A, Sato T, Naganuma M, et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008. 43(1):51-6. [Medline].

  • Miki C, Okita Y, Yoshiyama S, Araki T, Uchida K, Kusunoki M. Early postoperative application of extracorporeal leukocyte apheresis in ulcerative colitis patients: results of a pilot trial to prevent postoperative septic complications. J Gastroenterol. 2007 Jun. 42(6):508-9. [Medline].

  • Emmrich J, Petermann S, Nowak D, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Dig Dis Sci. 2007 Sep. 52(9):2044-53. [Medline].

  • Ruuska T, Lahdeaho ML, Sutas Y, Ashorn M, Gronlund J. Leucocyte apheresis in the treatment of paediatric ulcerative colitis. Scand J Gastroenterol. 2007 Nov. 42(11):1390-1. [Medline].

  • Zittan E, Ma GW, Wong-Chong N, et al. Ileal pouch-anal anastomosis for ulcerative colitis: a Canadian institution's experience. Int J Colorectal Dis. 2017 Feb. 32(2):281-5. [Medline].

  • Sandborn WJ, et al. A phase III randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab maintenance therapy in patients with moderately to severely active ulcerative colitis: PURSUIT-Maintenance. Presented at the American College of Gastroenterology, October 22, 2012 Las Vegas, NV.

  • Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov. 143(5):1218-26.e1-2. [Medline].

  • Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21. 354(9179):635-9. [Medline].

  • Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007 Nov. 42(11):1306-11. [Medline].

  • Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000 Jul. 24(7):851-6. [Medline].

  • Farouk R, Dozois RR, Pemberton JH, Larson D. Incidence and subsequent impact of pelvic abscess after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum. 1998 Oct. 41(10):1239-43. [Medline].

  • Shamberger RC, Hergrueter CA, Lillehei CW. Use of a gracilis muscle flap to facilitate delayed ileal pouch-anal anastomosis. Dis Colon Rectum. 2000 Nov. 43(11):1628-31. [Medline].

  • Karlbom U, Raab Y, Ejerblad S, Graf W, Thorn M, Pahlman L. Factors influencing the functional outcome of restorative proctocolectomy in ulcerative colitis. Br J Surg. 2000 Oct. 87(10):1401-8. [Medline].

  • Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998 Jun. 85(6):800-3. [Medline].

  • Ogilvie JW Jr, Goetz L, Baxter NN, Park J, Minami S, Madoff RD. Female sexual dysfunction after ileal pouch-anal anastomosis. Br J Surg. 2008 Jul. 95(7):887-92. [Medline].

  • Cornish JA, Tan E, Teare J, Teoh TG, Rai R, Darzi AW. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007 Aug. 50(8):1128-38. [Medline].

  • Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 Jul. 6(7):782-8. [Medline].

  • Falk A, Olsson C, Ahrne S, Molin G, Adawi D, Jeppsson B. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand J Gastroenterol. 2007 Aug. 42(8):973-85. [Medline].

  • Chia CS, Chew MH, Chau YP, Eu KW, Ho KS. Adenocarcinoma of the anal transitional zone after double stapled ileal pouch-anal anastomosis for ulcerative colitis. Colorectal Dis. 2008 Jul. 10(6):621-3. [Medline].

  • Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar. 105(3):501-23; quiz 524. [Medline].

  • Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015 Mar. 13(3):531-8. [Medline].

  • Sarigol S, Wyllie R, Gramlich T, et al. Incidence of dysplasia in pelvic pouches in pediatric patients after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999 Apr. 28(4):429-34. [Medline].

  • Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug. 16(8):1352-6. [Medline].

  • Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol. 2010 May. 105(5):1150-7. [Medline].

  • Andersson T, Lunde OC, Johnson E, Moum T, Nesbakken A. Long-term functional outcome and quality of life after restorative proctocolectomy with ileo-anal anastomosis for colitis. Colorectal Dis. 2011 Apr. 13(4):431-7. [Medline].

  • Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010 Jan. 16(1):112-24. [Medline].

  • Brooks M. FDA approves new indication for Simponi. Medscape Medical News. May 15, 2013. [Full Text].

  • Charron M, del Rosario JF, Kocoshis S. Use of technetium-tagged white blood cells in patients with Crohn's disease and ulcerative colitis: is differential diagnosis possible?. Pediatr Radiol. 1998 Nov. 28(11):871-7. [Medline].

  • Choi JS, Potenti F, Wexner SD, et al. Functional outcomes in patients with mucosal ulcerative colitis after ileal pouch-anal anastomosis by the double stapling technique: is there a relation to tissue type?. Dis Colon Rectum. 2000 Oct. 43(10):1398-404. [Medline].

  • Cottliar A, Fundia A, Boerr L, et al. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol. 2000 Sep. 95(9):2301-7. [Medline].

  • Cucchiara S, Celentano L, de Magistris TM, Montisci A, Iula VD, Fecarotta S. Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease. J Pediatr. 1999 Dec. 135(6):727-32. [Medline].

  • da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg. 2010 Jan. 97(1):65-9. [Medline].

  • Durno C, Sherman P, Harris K, et al. Outcome after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1998 Nov. 27(5):501-7. [Medline].

  • Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990 Nov 1. 323(18):1228-33. [Medline].

  • Fonkalsrud EW, Bustorff-Silva J. Reconstruction for chronic dysfunction of ileoanal pouches. Ann Surg. 1999 Feb. 229(2):197-204. [Medline]. [Full Text].

  • Fonkalsrud EW, Thakur A, Roof L. Comparison of loop versus end ileostomy for fecal diversion after restorative proctocolectomy for ulcerative colitis. J Am Coll Surg. 2000 Apr. 190(4):418-22. [Medline].

  • Gorfine SR, Bauer JJ, Harris MT, Kreel I. Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted?. Dis Colon Rectum. 2000 Nov. 43(11):1575-81. [Medline].

  • Hunt LE, Eichenberger MR, Petras R, Galandiuk S. Use of a microsatellite marker in predicting dysplasia in ulcerative colitis. Arch Surg. 2000 May. 135(5):582-5. [Medline].

  • Metcalf DR, Nivatvongs S, Sullivan TM, Suwanthanma W. A technique of extending small-bowel mesentery for ileal pouch-anal anastomosis: report of a case. Dis Colon Rectum. 2008 Mar. 51(3):363-4. [Medline].

  • Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006 Apr. 130(4):1030-8. [Medline].

  • Shamberger RC, Masek BJ, Leichtner AM, Winter HS, Lillehei CW. Quality-of-life assessment after ileoanal pull-through for ulcerative colitis and familial adenomatous polyposis. J Pediatr Surg. 1999 Jan. 34(1):163-6. [Medline].

  • Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995 May. 38(5):474-9. [Medline].

  • Bezzio C, Festa S, Saibeni S, Papi C. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Rev Gastroenterol Hepatol. 2017 Feb 6. [Medline].

  • Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disorder. It differs from Crohn's disease in that inflammation is limited to the colon, but may be associated with similar extra-intestinal manifestations (EIMs).

    1.5 CPD Credits Click here to take a test on this article and claim a certificate on MIMS Learning

    Section 1 Epidemiology and aetiology

    In Europe, the highest incidence rates are in Scandinavia (20-26 per 100,000) and the UK (19 per 100,000). The lowest incidence rates are found in southern (0.7-7 per 100,000) and eastern (8.1 per 100,000) European countries. North America and Canada have among the highest incidence rates of inflammatory bowel disease (IBD) in the world.1,2

    The incidence of UC is highest between the second and fourth decades of life.3

    Aetiology and classification

    The aetiology is unknown. Genetic factors contribute to disease pathogenesis. Patients with UC will have a first-degree relative with UC or IBD in up to 15% of cases. Several genes are linked to IBD, with different susceptibility among individuals.

    Disease expression is determined by one or more of the environmental factors implicated in IBD - previous appendicectomy, smoking, dietary factors, improved sanitation, oral contraceptives, vitamin D levels and psychological stress.

    The gut microbiota also plays a key part in the disease. No single organism is responsible, but there are reports of less diversity in the microbiota with IBD.

    The prevailing hypothesis is that inflammation is generated by dysregulated immunological handling of microbial antigens. New molecular techniques are revealing microbiota differences with diet and geographical locations.3

    Colonic disease is classified according to its distribution based on the Montreal classification: proctitis (E1), left-sided disease (E2) or pancolitis (E3).

    Several classifications developed for clinical trials define mild, moderate and severe disease. The one most easily applied to clinical practice is shown in table 1.

    Section 2 Making the diagnosis

    UC classically presents with diarrhoea, rectal bleeding, mucus and abdominal pain, symptoms that reflect colonic inflammation. Weight loss can occur and may be due to dietary modifications instigated by patients to minimise symptoms.

    The most common EIM presentations are arthralgia, arthritis, ankylosing spondylitis, scleritis, episcleritis and uveitis, erythema nodosum, pyoderma gangrenosum and primary sclerosing cholangitis.

    Clinical examination may reveal little except for tachycardia and pallor with severe disease and features of associated EIM.

    Rigid sigmoidoscopy is useful in examination because the characteristic feature of UC is rectal inflammation extending proximally in continuity. The features of rectal inflammation in increasing degrees of severity are loss of vascular pattern due to oedema, ulceration, exudates and various degrees of haemorrhage. Such findings are not diagnostic of UC and infectious colitis should be excluded before a diagnosis or relapse of UC is reached.

    Investigations
    Investigations depend on the setting. The aim in primary care is to make the diagnosis (new or relapse) and in secondary care, to confirm the diagnosis and assess the severity and extent of UC.

    In primary care, tests must include stool specimens to exclude infectious colitis, namely salmonella, shigella, Escherichia coli, Clostridium difficile or campylobacter and giardiasis in some cases. A raised CRP and iron deficiency anaemia support the diagnosis. Raised faecal calprotectin can be helpful if rectal bleeding is absent and the presentation mimics irritable bowel syndrome.

    Supporting findings include electrolyte disturbance due to fluid loss from the gut and dehydration, and abnormal LFTs, indicative of associated primary sclerosing cholangitis.

    A tentative diagnosis can be made in young patients presenting with one or more of the above symptoms and consistent haematological and biochemical changes only after excluding infections.

    In secondary care, the diagnosis is based on clinical, endoscopic and histological features. Diagnostic criteria are not routinely used, although the Copenhagen criteria (see box) can be helpful.

    Copenhagen criteria

    All criteria must be present

    • History of diarrhoea and/or rectal bleeding and pus for more than one week, or repeated episodes.
    • Characteristic endoscopic findings of continuous ulceration, vulnerability or granulated mucosa.
    • Histopathology consistent with ulcerative colitis (neutrophils within epithelial structures, cryptitis, crypt distortion, crypt abscesses).

    Section 3 Managing the condition

    The aim of therapy is to induce and maintain remission. The therapeutic approach, which depends on the extent and severity of the inflammation, is outlined in figure 1.

    Mesalazine
    Mesalazine preparations, containing the active moiety 5-aminosalicylic acid (5ASA), taken orally or topically, are first-line drugs with significant response rates and very few side- effects. The preparations differ in the release mechanism of 5ASA.

    Response rates of 40-80% and remission rates of 25-35% have been reported.

    Most oral preparations are also available as enemas or suppositories, used as monotherapy in left-sided colitis and as oral therapy in pancolitis.

    Studies show a synergistic effect when oral and topical therapy are co-prescribed to induce remission.4

    Prednisolone
    Prednisolone is first-line therapy for severe acute UC or for an incomplete response to mesalazine after 10-14 days.

    It is very effective at inducing remission, demonstrating complete remission rates of 58% and partial remission rates of 26% at 30 days. This efficacy is offset by short-term side-effects, particularly weight gain, acne and sleep disturbance.

    Early assessment in secondary care is recommended for steroid-refractory and steroid-dependent patients (defined as more than two relapses per year), so steroid-sparing drugs can be prescribed.

    The use of such drugs requires specialist monitoring because of the risk of potentially serious adverse events. These drugs include the thiopurines azathioprine and mercaptopurine, tacrolimus, and biological agents such as infliximab and adalimumab.

    Once remission is achieved, maintenance therapy reduces the risk of future relapse. The therapeutic options are mesalazine preparations or thiopurines. Long-term maintenance therapy is generally recommended for left-sided and pancolitis, and proctitis that relapses more than once a year.

    Surgery
    Surgery offers a cure and is indicated for disease refractory to medical therapy or complicated by dysplasia or cancer.3 The options are proctocolectomy with long-term ileostomy, or subtotal colectomy, proctectomy and ileal pouch.

    Pouch surgery can affect fertility and sexual function, although recent studies show that laparoscopic surgery reduces this risk.5

    Section 4 Prognosis and follow-up

    The prognosis is variable. In a five-year cohort follow-up study,6 more than half (59%) experienced one severe presentation followed by minor relapses and remission.

    The remainder experienced regular relapses and remissions.

    Patients should be educated about self-management and those on mesalazine maintenance therapy should have a twice-yearly renal function check.

    Patients with left-sided UC and pancolitis have an increased risk of developing colon cancer. Those with an eight-year history of pancolitis or a 15-year history of left-sided colitis should be enrolled in an endoscopic cancer surveillance programme.

    Section 5 Case study

    A 32-year-old man presented to the urgent IBD clinic with symptoms of diarrhoea, with a stool frequency of seven times per day to loose watery stool, associated with fresh blood and tenesmus.

    He had been diagnosed with UC three years ago, when his disease was limited to the rectum. He had stopped maintenance therapy and his last relapse was two years ago.

    Rigid sigmoidoscopy showed inflamed rectum with oedema and bleeding, but no ulceration.

    Oral therapy
    Stool cultures were sent and the patient was started on oral mesalazine 2.4g twice daily. Stool cultures showed Campylobacter jejuni.

    Mesalazine was continued and an antibiotic started. After 10 days, his diarrhoea had improved, but not completely resolved. Repeat stool culture was negative. Mesalazine suppository 1g daily was started.

    A colonoscopy two weeks later showed mild pancolitis. The suppository was replaced by mesalazine enema 2g at night.

    His symptoms settled after three weeks and the enemas were stopped. The patient remained on maintenance mesalazine 1.2g twice a day.

    Remission
    This case highlights a number of points. Patients with proctitis can maintain remission without therapy. In 25% of cases, the proctitis can extend to left-sided or pancolitis during the course of the disease. This has a bearing on the choice of first-line therapy.

    In this case, because of the severity of his symptoms, he was started on oral therapy. Suppositories were avoided because of the patient's history of tenesmus.

    One of the key learning points is that any relapses in UC may be due to an infection, and infection in patients with UC may trigger a relapse of the disease. Oral mesalazine was appropriate, provided the presence of campylobacter was not missed.

    Persistent symptoms after successful treatment of campylobacter indicated UC relapse. Suppositories were initially used, based on the previous diagnosis of proctitis.

    However, once disease extension was diagnosed by colonoscopy, they were replaced by an enema, to capture the synergistic effect of oral and topical mesalazine. Enemas can be stopped after two to three weeks. This patient should remain on long-term maintenance therapy.

    Section 6 Evidence base

    Clinical trials

    • Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-27.

    The main outcome was the reduction of a clinical activity index by at least 50% from baseline. A significant improvement in symptoms, but not remission, was observed.

    The results suggest that VSL#3 has a role in clinical practice in mild to moderate UC as an alternative to increasing 5ASA drugs, which can induce or exacerbate renal failure.

    • Lobaton T, Rodriguez-Moranta F, Lopez A et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013; 19(5): 1034-42.

    The outcome was the accuracy of calprotectin for the prediction of endoscopic activity and reliability of the rapid quantitative test, compared with the ELISA test.

    The rapid test correlated more closely with the Mayo endoscopic subscore than clinical or biomarkers.

    A cut-off of 280 microgram/g predicted endoscopic remission with strong correlation to a laboratory ELISA test, making it a useful tool for monitoring patients in primary care.

    • Frolkis AD, Dykeman J, Negron ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta- analysis of population-based studies. Gastroenterol 2013; 145(5): 996-1006.

    The main outcome was the change in surgery risk for IBD over time.

    The one-, five-, and 10-year risk of surgery was defined among patients with IBD diagnosed in the last half of the 20th century.

    The main finding related to UC was a decrease in the oneand 10-year risk of surgery over the four decades. The reduction in surgery can be attributed to changes in clinical practice.

    Guidelines

    • NICE. Ulcerative colitis. Management in adults, children and young people. CG166. London, NICE, June 2013.

    This has a good algorithm on inducing remission in UC based on the extent of disease (page 39). It is also worth looking at the section on bone health (page 257).

    • Mowat C, Cole A, Windsor A et al on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011. doi:10.1136/gut.2010.224154

    These guidelines include three key sections for GPs: safe prescribing of thiopurines in IBD and addressing patients' safety concerns, the importance of vaccination in IBD, and understanding surgery for UC.

    Click here to take a test on this article and claim a certificate on MIMS Learning

    Further resources

    • Feldman M, Friedman LS, Lawrence J. Sleisenger and Fordtran's Gastrointestinal and Liver Disease (ninth edition). Philadelphia, Saunders, 2010. Volume two, chapter 112 covers UC.

    Online resources

    • Crohn's and Colitis UK This charity offers, among other resources, a useful range of information sheets for patients, which are free to download.
    CPD IMPACT: EARN MORE CREDITS

    These further action points may allow you to earn more credits by increasing the time spent and the impact achieved.

    • Organise an audit of patients in your practice who have UC and review their repeat prescriptions for mesalazine.
    • Review NICE and British Society of Gastroenterology guidelines for updates on UC management.
    • Arrange a meeting with the consultant gastroenterologist and surgeon to discuss a protocol for referring patients with UC.

    References

    1. Burisch J, Munkholm P. Curr Opin Gastroenterol 2013; 29(4): 357-62.

    2. Burisch J, Pedersen N, Cukovic-Cavka S et al. Gut 2013. doi: 10.1136/gutjnl-2013-304636

    3. Ponder A, Long MD. Clin Epidemiol 2013; 5: 237-47.

    4. Marteau P, Probert CS, Lindgren S et al. Gut 2005; 54(7): 960-5.

    5. Beyer-Berjot L, Maggiori L, Birnbaum D et al. Ann Surg 2013; 258(2): 275-82.

    6. Henriksen M, Jahnsen J, Lygren I et al. Scand J Gastroenterol 2006; 41(9): 1037-43.

    • Dr Naila Arebi, consultant gastroenterologist, The London Clinic and St Mark's Hospital, London.

    0 Thoughts to “Colitis Case Study

    Leave a comment

    L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *